Genetic Engineering in the Press by GEG

The positive results in the clinical trial help validate Alnylam's $7 billion market valuation and pave the way for more drugs based on RNAi technology.

In this Review, thez authors discuss how CRISPR–Cas can affect the next generation of drugs by accelerating the identification and validation of high-value targets, uncovering high-confidence biomarkers and developing differentiated breakthrough therapies.

In an advance that could lead to the development of better treatments for viral pathogens, such as Zika, a team of scientists at the California NanoSystems Institute at UCLA are developing a more accurate and more cost-effective DNA-screening system based on gene-editing technology.

Circassia could not beat the placebo in a Phase III trial for cat allergy last year, which immediately drove its stock down by 65% and led to the halt of clinical trials across its allergy pipeline. Today, its shares are back up by 30% after the announcement of a deal between the British biotech and AstraZeneca.